JP7617134B2 - Gpr52アゴニスト活性を有する置換3-フェノキシアゼチジン-1-イル-ピラジン - Google Patents

Gpr52アゴニスト活性を有する置換3-フェノキシアゼチジン-1-イル-ピラジン Download PDF

Info

Publication number
JP7617134B2
JP7617134B2 JP2022559709A JP2022559709A JP7617134B2 JP 7617134 B2 JP7617134 B2 JP 7617134B2 JP 2022559709 A JP2022559709 A JP 2022559709A JP 2022559709 A JP2022559709 A JP 2022559709A JP 7617134 B2 JP7617134 B2 JP 7617134B2
Authority
JP
Japan
Prior art keywords
μmol
mixture
room temperature
group
stirred
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022559709A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023522307A (ja
JP2023522307A5 (cg-RX-API-DMAC7.html
Inventor
カイ ゲルラッハ
バルバラ ベルターニ
マルコ フェッラーラ
ジャコモ フォッサティ
スコット ホブソン
ウータ フリーデリーケ レッセル
フランク ルンゲ
グレイム センプレ
ウルズラ ミュラー-ヴィエイラ
ユリアン ウィッピッチ
イフェン ション
Original Assignee
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
アリーナ ファーマシューティカルズ, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング, アリーナ ファーマシューティカルズ, インコーポレイテッド filed Critical ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2023522307A publication Critical patent/JP2023522307A/ja
Publication of JP2023522307A5 publication Critical patent/JP2023522307A5/ja
Application granted granted Critical
Publication of JP7617134B2 publication Critical patent/JP7617134B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2022559709A 2020-03-30 2021-03-29 Gpr52アゴニスト活性を有する置換3-フェノキシアゼチジン-1-イル-ピラジン Active JP7617134B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063001640P 2020-03-30 2020-03-30
US63/001,640 2020-03-30
PCT/EP2021/058099 WO2021198149A1 (en) 2020-03-30 2021-03-29 Substituted 3-phenoxyazetidin-1-yl-pyrazines having gpr52 agonistic activity

Publications (3)

Publication Number Publication Date
JP2023522307A JP2023522307A (ja) 2023-05-30
JP2023522307A5 JP2023522307A5 (cg-RX-API-DMAC7.html) 2024-05-23
JP7617134B2 true JP7617134B2 (ja) 2025-01-17

Family

ID=75362607

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022559709A Active JP7617134B2 (ja) 2020-03-30 2021-03-29 Gpr52アゴニスト活性を有する置換3-フェノキシアゼチジン-1-イル-ピラジン

Country Status (20)

Country Link
US (1) US11780827B2 (cg-RX-API-DMAC7.html)
EP (1) EP4126850B1 (cg-RX-API-DMAC7.html)
JP (1) JP7617134B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220161454A (cg-RX-API-DMAC7.html)
CN (1) CN115697997B (cg-RX-API-DMAC7.html)
AR (1) AR121675A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021250303A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022018996A2 (cg-RX-API-DMAC7.html)
CA (1) CA3176265A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022014886A2 (cg-RX-API-DMAC7.html)
CR (1) CR20220554A (cg-RX-API-DMAC7.html)
DO (1) DOP2022000203A (cg-RX-API-DMAC7.html)
EC (1) ECSP22080683A (cg-RX-API-DMAC7.html)
IL (1) IL296823A (cg-RX-API-DMAC7.html)
JO (1) JOP20220235A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022012067A (cg-RX-API-DMAC7.html)
PE (1) PE20221918A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022552553A1 (cg-RX-API-DMAC7.html)
TW (1) TW202204343A (cg-RX-API-DMAC7.html)
WO (1) WO2021198149A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4139284A1 (en) 2020-04-22 2023-03-01 Neurocrine Biosciences, Inc. Gpr52 modulators and methods of use
WO2023041432A1 (en) 2021-09-14 2023-03-23 Boehringer Ingelheim International Gmbh 3-phenoxyazetidin-1-yl-heteroaryl pyrrolidine derivatives and the use thereof as medicament
CN119143731B (zh) * 2024-09-13 2025-08-26 中国海洋大学 一种吡嗪酰胺类化合物及其制备方法和应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002533454A (ja) 1998-12-23 2002-10-08 イーライ・リリー・アンド・カンパニー 芳香族アミド類
WO2009107391A1 (ja) 2008-02-27 2009-09-03 武田薬品工業株式会社 6員芳香環含有化合物
WO2011093352A1 (ja) 2010-01-27 2011-08-04 武田薬品工業株式会社 チアゾール誘導体
WO2011145735A1 (ja) 2010-05-21 2011-11-24 武田薬品工業株式会社 チアゾール誘導体
WO2012020738A1 (ja) 2010-08-09 2012-02-16 武田薬品工業株式会社 複素環化合物およびその用途
WO2012076063A1 (en) 2010-12-10 2012-06-14 Rottapharm S.P.A. Pyridine amide derivatives as ep4 receptor antagonists
JP2018519253A (ja) 2015-04-29 2018-07-19 アリーナ ファーマシューティカルズ, インコーポレイテッド Gpr52に関連する障害の治療または予防に有用なgpr52のモジュレーターとしての1−ヘテロアリール−インドリン−4−カルボキサミド

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0808668D0 (en) * 2008-05-13 2008-06-18 Univ Aberdeen Materials and methods relating to a G-protein coupled receptor
EP2298731A4 (en) 2008-06-25 2011-09-21 Takeda Pharmaceutical AMIDE COMPOUND
EP2518054A1 (en) * 2009-12-24 2012-10-31 Takeda Pharmaceutical Company Limited Amide compound
AU2016324317A1 (en) * 2015-09-17 2018-03-08 Coda Biotherapeutics, Inc. Compositions and methods for treating neurological disorders

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002533454A (ja) 1998-12-23 2002-10-08 イーライ・リリー・アンド・カンパニー 芳香族アミド類
WO2009107391A1 (ja) 2008-02-27 2009-09-03 武田薬品工業株式会社 6員芳香環含有化合物
WO2011093352A1 (ja) 2010-01-27 2011-08-04 武田薬品工業株式会社 チアゾール誘導体
WO2011145735A1 (ja) 2010-05-21 2011-11-24 武田薬品工業株式会社 チアゾール誘導体
WO2012020738A1 (ja) 2010-08-09 2012-02-16 武田薬品工業株式会社 複素環化合物およびその用途
WO2012076063A1 (en) 2010-12-10 2012-06-14 Rottapharm S.P.A. Pyridine amide derivatives as ep4 receptor antagonists
JP2018519253A (ja) 2015-04-29 2018-07-19 アリーナ ファーマシューティカルズ, インコーポレイテッド Gpr52に関連する障害の治療または予防に有用なgpr52のモジュレーターとしての1−ヘテロアリール−インドリン−4−カルボキサミド

Also Published As

Publication number Publication date
AU2021250303A1 (en) 2022-09-22
US11780827B2 (en) 2023-10-10
IL296823A (en) 2022-11-01
JOP20220235A1 (ar) 2022-09-28
MX2022012067A (es) 2022-10-13
DOP2022000203A (es) 2022-11-30
ECSP22080683A (es) 2022-11-30
CA3176265A1 (en) 2021-10-07
TW202204343A (zh) 2022-02-01
CO2022014886A2 (es) 2022-10-31
PE20221918A1 (es) 2022-12-29
KR20220161454A (ko) 2022-12-06
JP2023522307A (ja) 2023-05-30
BR112022018996A2 (pt) 2022-11-01
WO2021198149A1 (en) 2021-10-07
CN115697997B (zh) 2024-07-30
EP4126850B1 (en) 2024-04-17
AR121675A1 (es) 2022-06-29
EP4126850A1 (en) 2023-02-08
US20220356172A1 (en) 2022-11-10
CR20220554A (es) 2023-01-09
CN115697997A (zh) 2023-02-03
PH12022552553A1 (en) 2024-01-03

Similar Documents

Publication Publication Date Title
TWI543974B (zh) 苯基-3-氮雜-雙環[3.1.0]己-3-基-甲酮及其作為藥物之用途
WO2004110986A1 (ja) ベンズアミド誘導体又はその塩
JP2010505842A (ja) トロンビン受容体拮抗薬としての二環式誘導体および三環式誘導体
AU2018216040A1 (en) OGA inhibitor compounds
CN102753540B (zh) α4β2神经元烟碱型乙酰胆碱受体的配体
CA3120268A1 (en) Heterocyclic derivatives as nav1.7 and nav1.8 blockers
US11780827B2 (en) Substituted 3-phenoxyazetidin-1-yl-pyrazines
JP5820541B2 (ja) mGlu5のポジティブアロステリックモジュレーターとしての4−アリールイミダゾール誘導体
US12115157B2 (en) 3-phenoxyazetidin-1-yl-heteroaryl pyrrolidine derivatives and the use thereof as medicament
AU2003243089B2 (en) Novel compounds, their use and preparation
EP3810593A1 (en) Oga inhibitor compounds
CN102741239B (zh) 作为α4β2烟碱型乙酰胆碱受体配体的双环化合物
EP2266976B1 (en) Fused ring thrombin receptor antagonists
DE602005006018T2 (de) Arylpiperazinderivate und deren verwendung als für den dopamin-d3-rezeptor selektive liganden
US9604926B2 (en) Highly selective sigma receptor radioligands
JP2017524736A (ja) アルファ7−ニコチン性アセチルコリン受容体活性を調節するためのキヌクリジン化合物
WO2024091541A1 (en) Compounds and compositions as gpr52 modulators
WO2019163865A1 (ja) 含窒素複素環を有するジベンゾアゼピン誘導体
WO2018139471A1 (ja) ジベンゾジアゼピン誘導体
PL245933B1 (pl) (Chinolino lub izochinolino) sulfonamidy amin cyklicznych, kompozycja je zawierająca, sposób ich wytwarzania oraz ich zastosowanie medyczne
EP2958912A1 (en) Pyridine derivatives as 5-ht6 receptor antagonists
JP2016106072A (ja) プロペラン誘導体
PL237865B1 (pl) Amidy kwasu 2-arylo-pirolokarboksylowego i ich zastosowanie
HK1175782B (en) BICYCLIC COMPOUNDS AS α4β2 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240327

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240327

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241203

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250106

R150 Certificate of patent or registration of utility model

Ref document number: 7617134

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150